3/5Vitro Biopharma, Inc.: Going-concern doubt

Market data

n/a: no ticker symbol on the filing.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after (window still open until 2026-10-18): none reported so far.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-06-20 to 2026-10-18. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2026-07-31)

Why this score: quarterly (unaudited) disclosure